1. Home
  2. Browse
  3. HRA003874
HRA003874
   HRA003874.xlsx
Title:
Overcoming resistance to immunotherapy by targeting GPR84 in MDSCs
Release date:
2025-01-31
Description:
MDSCs were found to gradually accumulate in the tumor progression. Although the roles of MDSCs in promoting tumor growth and inhibiting immune response have been extensively explored, currently, there are still no effective means for targeting MDSCs clinically. The deficiency of specific markers of MDSCs was responsible for the limited strategy to eliminating in clinic. This study identified that GPR84 was exclusively overexpressed on MDSCs and drives the immunosuppression on CD8+T cells by inhibiting PD-L1 degradation in lysosomes. GPR84 antagonism combined with an anti-PD-1 antibody enhanced the antitumor responses. Therefore, targeting GPR84 enhanced anti-PD-1 efficacy in esophageal cancer and other malignant tumors. This combination therapy has potential for tumor therapy in clinic.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA014498
Study type:
Disease Study
Disease name:
esophageal cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002227
DAC name:
MDSCs dataset
Contact person:
Zhang Yi
Email:
yizhang@zzu.edu.cn
Description:
MDSCs were seperated from human esophageal carcinoma tissues, and then RNA-seq was performed.
Individuals & samples
Files
Request Data
Submitter:   Zhang Yi / yizhang@zzu.edu.cn
Organization:   The First Affiliated Hospital of Zhengzhou University
Submission date:   2023-01-31
Requests:   -